Elarekibep is a Recombinant Protein owned by AstraZeneca, and is involved in 4 clinical trials, of which 3 were completed, and 1 is ongoing.

Elarekibep acts by antagonizing interleukin 4 receptor alpha (IL-4RA) and blocks the action of IL-4 and IL-13. IL-4 and IL-13 are the primary cytokines secreted mainly by T helper type 2 (Th2) cells and activate pSTAT6 that helps in regulation of transcription process and is involved in allergic inflammatory diseases. The drug candidate exhibits therapeutic activity by inhibiting IL-4RA induced pSTAT6 mediated signalling and ameliorates the disease condition.

The revenue for Elarekibep is expected to reach a total of $352m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Elarekibep NPV Report.

Elarekibep was originated by Pieris Pharmaceuticals and is currently owned by AstraZeneca. Pieris Pharmaceuticals is the other company associated in development or marketing of Elarekibep.

Elarekibep Overview

Elarekibep is under development for the treatment of moderate to severe asthma. The drug candidate is administered through an inhalation and intravenous route. It targets the interleukin-4 receptor alpha (IL4RA). It is based on Anticalin platform technology.

Pieris Pharmaceuticals Overview

Pieris Pharmaceuticals (Pieris) is a clinical-stage biotechnology company that carries out the discovery and development of anticalin-based drugs. The company’s pipeline product includes inhaled IL-4Ra antagonist Anticalin protein. It offers drug candidates such as PRS-060/AZD1402, PRS-220, PRS-440, PRS-342 and PRS-352, among others. Pieris also carries out AstraZenca programs and Genetech programs against respiratory diseases. The company offers therapeutics for the treatment of respiratory diseases, oncology and other diseases. It leverages Anticalin technology platform to develop and advance its pipeline candidates. Pieris collaborates with AstraZeneca Plc, Boston Pharmaceuticals, Servier SAS, Genentech and Seattle Genetics Inc to develop drug candidates. It operates in the US, Australia and Germany. Pieris is headquartered in Boston, Massachusetts, the US.

The company reported revenues of (US Dollars) US$31.4 million for the fiscal year ended December 2021 (FY2021), an increase of 7.1% over FY2020. The operating loss of the company was US$48.2 million in FY2021, compared to an operating loss of US$33.9 million in FY2020. The net loss of the company was US$45.7 million in FY2021, compared to a net loss of US$37.2 million in FY2020. The company reported revenues of US$3.7 million for the second quarter ended June 2022, a decrease of 66.3% over the previous quarter.

Quick View – Elarekibep

Report Segments
  • Innovator
Drug Name
  • Elarekibep
Administration Pathway
  • Inhalational
  • Intravenous
Therapeutic Areas
  • Respiratory
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.